Sciclone Pharmaceuticals
SCLN
SCLN was delisted on the 13th of October, 2017.
142 hedge funds and large institutions have $423M invested in Sciclone Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 56 increasing their positions, 39 reducing their positions, and 18 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 39
33% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 18
21% more capital inflows, than outflows
Capital inflows: $67.5M | Capital outflows: $55.5M
4% more funds holding
Funds holding: 136 → 142 (+6)
1.79% more ownership
Funds ownership: 72.49% → 74.28% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
82% less call options, than puts
Call options by funds: $214K | Put options by funds: $1.17M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GLG Partners
London,
United Kingdom
|
+$12.3M |
| 2 |
Two Sigma Investments
New York
|
+$6.99M |
| 3 |
Renaissance Technologies
New York
|
+$4.56M |
| 4 |
Oxford Asset Management
Oxford,
United Kingdom
|
+$4M |
| 5 |
GAM Holding
Zurich,
Switzerland
|
+$3.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nantahala Capital Management
New Canaan,
Connecticut
|
-$18.5M |
| 2 |
Stonepine Capital Management
Bend,
Oregon
|
-$14.5M |
| 3 |
Pine River Capital Management
Minnetonka,
Minnesota
|
-$3.98M |
| 4 |
BlackRock
New York
|
-$2.45M |
| 5 |
Systematic Financial Management
Teaneck,
New Jersey
|
-$1.32M |
SCLN Hedge Fund Activity: Q2 2017 in Review
142 of the 4,024 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals (SCLN) for Q2 2017, worth a combined $423M — up 16% from $366M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new SCLN positions and 18 closed out — a net gain of 6 holders — while 56 added to existing stakes and 39 trimmed.
The largest buyer was GLG Partners, adding an estimated $12.3M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $18.5M sold.
- 142 institutional investors held Sciclone Pharmaceuticals (SCLN) as of Q2 2017, up from 136 in Q1 2017.
- Funds reported $423M of Sciclone Pharmaceuticals stock for Q2 2017, up 16% quarter-over-quarter.
- 24 funds opened new Sciclone Pharmaceuticals positions in Q2 2017 and 18 closed out, a net change of +6 holders.
- The largest Sciclone Pharmaceuticals buyer in Q2 2017 was GLG Partners, an estimated $12.3M added.
- The largest Sciclone Pharmaceuticals seller in Q2 2017 was Nantahala Capital Management, an estimated $18.5M sold.
Based on aggregated 13F filings for Q2 2017.